Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Danon Disease Clinical Trial

Official title:

A Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03882437
• Other study ID #: RP-A501-0219
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 17, 2019
• Est. completion date: March 24, 2025

Study information

• Verified date: February 2023
• Source: Rocket Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized open-label Phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD).

Description:

The study is a non-randomized open-label Phase I clinical trial to characterize the safety and toxicity associated with infusion of a recombinant adeno-associated serotype 9 (rAAV9) capsid containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD).

During the course of the study, approximately 7-10 male subjects age 8 and over will receive a single intravenous (IV) infusion of the IP. Prior to infusion of IP, rituximab and sirolimus will be administered prophylactically.

All patients are planned to be followed for 36 months after investigational product administration. After the end of the follow-up period, patients will enter a Long-Term Follow-Up (LTFU) study enabling follow-up for an additional 2 to 5 years post-IP administration.

The study will also enable an initial evaluation of whether or not the IP results in cardiomyocyte and skeletal muscle transduction and gene expression and preliminary assessment of the extent of cardiomyocyte and histologic correction. Additionally, a preliminary evaluation of clinical stabilization following infusion will also be made.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 7
• Est. completion date: March 24, 2025
• Est. primary completion date: March 24, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 8 Years and older

Eligibility

Main Criteria for Inclusion:

The study will enroll adult and pediatric males with a confirmed diagnosis of DD. Patients may be of any race or ethnicity. Patients and/or competent custodial parents must provide informed written consent and meet all of the enrollment criteria as detailed subsequently to be eligible to participate.

1. DD diagnosis with any confirmed LAMP2 mutation(s).

2. Cardiac involvement as documented by at least one abnormal finding on electrocardiogram (ECG), echocardiogram, gadolinium-enhanced cardiac magnetic resonance imaging (MRI), or electrophysiology study.

3. Age =15 years for cohorts 1 and 2; 8-14 years for cohorts 1A.

4. Male gender.

5. New York Heart Association (NYHA) Class II or III.

6. Adequate hematologic function as defined by hemoglobin, absolute neutrophil count (ANC), and platelet count = lower limit of normal (LLN).

7. Adequate hepatic function as defined by:

1. AST and ALT =10.0×ULN or GGT =2.0×ULN (transaminase elevations in DD are considered extensively to result from muscle injury; hence the relatively high upper limit for transaminases and consideration of GGT level, and the presence of additional hepatic eligibility markers of bilirubin and PT/INR).

2. Serum bilirubin =1.2×ULN (i.e., Grade =1 bilirubin increase).

3. PT/INR =1.2×ULN (in the absence of anticoagulation).

4. Absence of cirrhosis or other signs of inflammation on liver ultrasound

8. Adequate renal function as defined by creatinine =ULN.

9. Ability to provide informed consent (for adult patients and parents/legal guardians of pediatric patients) and assent (for patients age 15-17).

10. Ability to comply with study procedures including investigational therapy and follow-up evaluations.

11. Able to walk >150 meters unassisted during the 6MWT.

12. Patient has received meningococcal vaccination recommended by Centers for Disease Control as appropriate for age and health condition (vaccination must be performed at least 6 weeks prior to IP administration).

Main Criteria of Exclusion:

Patients meeting any of the following criteria are not eligible for study participation:

1. I.V. therapy with positive inotropes, vasodilators, or diuretics within the 30 days prior to enrollment (i.e., patient must be stable on oral medical therapy).

2. Prior cardiac transplantation or prior transplant of other organ (lung, liver, other).

3. Prior cardiac surgery and/or percutaneous cardiac intervention for arteriothrombotic complications, or valvuloplasty.

4. Presence or requirement of a Left Ventricular Assisted Device (LVAD).

5. History of intracardiac thrombosis or arteriothromboembolic events including stroke or transient ischemic attack (TIA).

6. Left ventricular ejection fraction (LVEF) <40% at baseline.

7. History of the following prior arteriothromboembolic complications: myocardial infarction or unstable angina.

8. Significant (greater than moderate) valvular stenosis or regurgitation on echocardiogram.

9. Requires mechanical ventilation.

10. Anti-AAV9 neutralizing antibody titer >1:40.

11. Concurrent enrollment in any other clinical investigation involving use of an investigational agent for the treatment of CHF or cardiomyopathy.

12. Active hepatitis B or C infection (including patients with positive hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B core antibody (HBcAb), or detectable hepatitis B virus (HBV) or hepatitis C virus (HCV) viral load). Patients with previous, adequately resolved HBV or HCV are eligible.

13. Significant medical conditions including documented human immunodeficiency virus (HIV) infection, active viral or other hepatitis, poorly-controlled hypertension or diabetes, poorly controlled cardiac arrhythmia, or uncontrolled viral, bacterial, or fungal infection.

14. Any concomitant medical or psychiatric condition that in the opinion of the Investigator renders the patient unfit for study participation or at higher than acceptable risk for study participation.

15. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or other carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years.

16. Any contraindication to use of sirolimus which includes hypersensitivity to sirolimus or HC-60 (polyoxyl 60 hydrogenated castor oil).

17. Active or latent tuberculosis.

Related Conditions & MeSH terms

• Danon Disease

Intervention

Biological:
• RP-A501
RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.

Locations

Country	Name	City	State
United States	University of Colorado	Aurora	Colorado
United States	University of California, San Diego	La Jolla	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Rocket Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute Common Terminology Criteria (NCI CTCAE)	Evaluation of safety associated with RP-A501	3 years
Primary	Number of participants within each dose level cohort with treatment-related adverse events as assessed by United States (US) National Cancer Institute Common Terminology Criteria (NCI CTCAE)	Assessment of safety at both doses (single IV administration)	3 years
Primary	Evaluation of cardiomyocyte histologic correction following administration of RP-A501 via endomyocardial biopsy	Assessment of cardiomyocyte histologic correction following administration of RP-A501 via endomyocardial biopsy	3 years
Primary	Preliminary evaluation of clinical stabilization of cardiomyopathy following administration of RP-A501 via cardiopulmonary testing	Assessment of clinical stabilization of cardiomyopathy following infusion of RP-A501 via cardiopulmonary testing	3 years
Secondary	Determination of the percentage of patients in whom RP-A501 resulted in a sustained improvement or stabilization in cardiovascular pathophysiology	Evaluation of sustained improvement or stabilization in cardiovascular pathophysiology as assessed by medical evaluation, radiographic evaluation of cardiac structure and function, and cardiopulmonary exercise/physiologic parameters	3 years
Secondary	Determination of the percentage of patients in whom cardiomyocytes corrected LAMP2B gene and/or protein	Evaluation of the percentage of patients in whom cardiomyocytes contain the corrected LAMP2B gene and/or protein and improvement in DD-associated histologic abnormalities and when feasible to quantify the extent of genetic and histologic correction in the myocardium.	3 years
Secondary	Determination and characterization of immunologic response to RP-A501	Assessment of potential immunogenicity to the components of the investigational product	3 years
Secondary	Determination of the percentage of patients who require and/or receive treatment for heart failure following RP-A501	Assessment of the percentage of patients who require and/or receive subsequent cardiac transplantation, left ventricular assist device (LVAD), implantable cardioverter-defibrillator or pacemaker placement, electrophysiologic ablative procedure for cardiac conduction aberrancy or subsequent hospitalizations for heart failure.	3 years
Secondary	Evaluation of overall survival	Assessment of overall survival post RP-A501	3 years